# Clinical Outcomes Between Anticoagulation and DAPT Therapy in AF Patients Successfully Undergoing LAAO

Study · id `cardio:ct-nct04135677` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04135677](<https://clinicaltrials.gov/study/NCT04135677>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04135677

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 826 participants.

## Technical summary

Registry record NCT04135677. Randomized; triple masking; primary purpose prevention. Start 2022-11-11 (actual); primary completion 2024-10-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 826 participants (planned count; ClinicalTrials.gov record NCT04135677, source copy `cardio:ctgov-nct04135677-2022-11-15`, retrieved 2026-10-26)
- Started: 2022-11-11 (actual) (ClinicalTrials.gov record NCT04135677, source copy `cardio:ctgov-nct04135677-2022-11-15`, retrieved 2026-10-26)
- Primary completion: 2024-10-01 (anticipated) (ClinicalTrials.gov record NCT04135677, source copy `cardio:ctgov-nct04135677-2022-11-15`, retrieved 2026-10-26)
- Completion: 2024-10-30 (anticipated) (ClinicalTrials.gov record NCT04135677, source copy `cardio:ctgov-nct04135677-2022-11-15`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT04135677, source copy `cardio:ctgov-nct04135677-2022-11-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04135677-2022-11-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Clinical Outcomes Between Anticoagulation and DAPT Therapy in AF Patients Successfully Undergoing LAAO
- Condition: Left Atrial Appendage Thrombosis
- Condition: Thrombi
- Condition: Stroke
- Intervention (Drug): Rivaroxaban
- Intervention (Drug): DAPT
- Lead sponsor: Shanghai Zhongshan Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Rivaroxaban (`cardio:rivaroxaban`)
- Registry lists this organization as the lead sponsor: Shanghai Zhongshan Hospital (`cardio:org-shanghai-zhongshan-hospital`)

## Provenance

Content hash: 8595bf02c856529d3e3ee147ebf063adaacd61048630753f182a3cc589ffe2b4
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
